Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, Kentucky
PSTV•Total contracted coverage rises
Total contracted coverage for the CNSide CSF assay rose to about 127 million people.
Medical Mutual coverage expands CNSide access
Plus Therapeutics signed a regional coverage agreement with Medical Mutual for the CNSide cerebrospinal fluid tumor cell enumeration assay, effective July 1, 2026.
Coverage spans about 1.2 million members across Ohio and Kentucky.
